BCL2A1is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BCL2A1is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 110, Issue 11, Pages 4321-4326
Publisher
Proceedings of the National Academy of Sciences
Online
2013-02-28
DOI
10.1073/pnas.1205575110
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant Melanoma
- (2015) William D. Tap et al. NEOPLASIA
- PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
- (2011) K. H. T. Paraiso et al. CANCER RESEARCH
- BCL2A1: the underdog in the BCL2 family
- (2011) M Vogler CELL DEATH AND DIFFERENTIATION
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of Bfl-1 with N-aryl maleimides
- (2010) John R. Cashman et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032
- (2010) Jonas N Søndergaard et al. Journal of Translational Medicine
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- The landscape of somatic copy-number alteration across human cancers
- (2010) Rameen Beroukhim et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
- (2010) E. W. Joseph et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Integrating BRAF/MEK inhibitors into combination therapy for melanoma
- (2009) K S M Smalley et al. BRITISH JOURNAL OF CANCER
- Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice
- (2009) Nathalie Dhomen et al. CANCER CELL
- GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer
- (2009) Kenneth L. Scott et al. NATURE
- SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas
- (2009) Adam J Bass et al. NATURE GENETICS
- BrafV600E cooperates with Pten loss to induce metastatic melanoma
- (2009) David Dankort et al. NATURE GENETICS
- Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
- (2009) A. C. Faber et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia
- (2008) M. Vogler et al. BLOOD
- Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma
- (2008) L. Paoluzzi et al. BLOOD
- Modeling Genomic Diversity and Tumor Dependency in Malignant Melanoma
- (2008) W. M. Lin et al. CANCER RESEARCH
- The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel
- (2008) N. K. Haass et al. CLINICAL CANCER RESEARCH
- Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic
- (2008) Mark S. Cragg et al. JOURNAL OF CLINICAL INVESTIGATION
- CDK8 is a colorectal cancer oncogene that regulates β-catenin activity
- (2008) Ron Firestein et al. NATURE
- Novel MITF targets identified using a two-step DNA microarray strategy
- (2008) Keith S. Hoek et al. Pigment Cell & Melanoma Research
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now